Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY2599023 (DTX201) in Adults With Severe Hemophilia A
NCT03588299Phase 2Completed
- Sponsor
- Bayer
- Start
- Nov 2018
- Primary completion
- Sep 2026
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 6
01
Overview
A Phase 2 trial of peboctocogene camaparvovec in hemophilia A, sponsored by Bayer. Started Nov 2018; status: completed.
02
Drugs
peboctocogene camaparvovec
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT03588299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03588299.